110 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint … the anticipated benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other
6-K
GLPG
Galapagos NV
1 May 24
Current report (foreign)
5:10pm
: Each new share to be issued by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Warrant B shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlement to dividends and other distributions … shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlement to dividends and other distributions
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
products, if any, statements regarding the potential attributes and benefits of our product candidates, including indications, dosing and treatment … , or efficacy concerns, or any other reasons), risks related to the potential benefits and risks related to our current collaborations, including our plans
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
. Benefits and expenses Benefits To align to market practice and help enable Board members fulfil their duties. The Company provides administrative support … across the Company. Benefits Competitive benefits are provided to attract and retain executives, contribute towards retirement planning and provide
6-K
EX-99.4
bcee2
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.5
3aodt2d4bb7s
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
zqf3hks1k1am3
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.3
8nkf3v4txp9h
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
d3f69hrmygj 40ww
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
EX-99.1
lf6t 81tc
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
o6ln9nqc9 hghh4iom
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
awbmvnzdj
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
rfw8ip7ks5w o3k6s
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
S-8
EX-99.1
ak803zmic5 e2n
4 Dec 23
Registration of securities for employees
5:16pm